Tempus AI, Predicta Expand Genomics Test for Blood Cancer

Chicago, Illinois, U.S. | April 15, 2026

Tempus AI, Inc., in collaboration with Predicta Biosciences, has announced the expansion of access to its ultrasensitive whole-genome sequencing (WGS) assay, GenoPredicta™, designed to advance precision oncology and measurable residual disease (MRD) monitoring in hematologic malignancies. This collaboration represents a significant step forward in integrating artificial intelligence, genomics, and liquid biopsy technologies to enable deeper molecular insights and improve clinical research and therapeutic development. The assay delivers high-resolution genomic profiling from peripheral blood or bone marrow, offering a scalable and minimally invasive solution to support early detection, treatment optimization, and disease monitoring in blood cancers.

Ultrasensitive Genomic Profiling Enhances Cancer Detection

The GenoPredicta™ assay introduces a powerful advancement in cancer diagnostics by combining flow cytometry with whole-genome sequencing, enabling the detection of genetic alterations such as single nucleotide variants (SNVs), insertions/deletions (indels), copy number variations (CNVs), and structural variants (SVs).

Notably, the assay can identify genomic changes from as few as 50 tumor cells, achieving sensitivity levels as low as one cancer cell among one million healthy cells, which significantly expands testing capabilities in patients with low tumor burden. This level of sensitivity allows clinicians and researchers to gain comprehensive insights into tumor biology, risk stratification, and therapy resistance mechanisms, making it a valuable tool in both clinical research and precision medicine applications.

AI-Driven Platform Supports Precision Medicine and Clinical Trials

The collaboration between Tempus and Predicta Biosciences highlights the growing importance of AI-enabled diagnostic platforms in advancing oncology research and drug development. The GenoPredicta™ assay is currently available to life sciences partners for exploratory research and clinical development programs, supporting biomarker discovery and optimizing clinical trial design.

By consolidating multiple testing modalities into a single unified workflow, the assay replaces traditional fragmented diagnostic approaches, improving efficiency and data integration. Importantly, the assay demonstrates 100% concordance between peripheral blood and bone marrow samples, reducing the need for invasive biopsies while maintaining high diagnostic accuracy. This innovation aligns with the broader shift toward non-invasive, data-driven healthcare solutions that enhance patient experience and clinical outcomes.

Expanding Access to Advanced Oncology Diagnostics

The commercial expansion of GenoPredicta™ reflects strong demand for next-generation diagnostic tools that can support both research and clinical applications. The assay has already been clinically validated in multiple myeloma and plasma cell disorders, with broader applications under investigation. By enabling deep molecular characterization of hematologic malignancies, the technology supports earlier intervention strategies and more personalized treatment approaches. Additionally, the collaboration builds on foundational research in cancer genomics, reinforcing the role of integrated omics and AI technologies in transforming the standard of care in oncology.

Strategic Implications for MedTech and Precision Oncology

The partnership between Tempus and Predicta Biosciences underscores a key trend in the healthcare industry, where technology companies and biotech innovators collaborate to accelerate precision medicine. By combining advanced sequencing technologies with artificial intelligence and real-world data platforms, the companies are creating scalable solutions that can be applied across a wide range of cancer types. This approach not only enhances diagnostic accuracy but also supports the development of targeted therapies and personalized treatment strategies, ultimately improving patient outcomes.

The expansion of the GenoPredicta™ assay marks a significant milestone in the evolution of AI-driven precision oncology and advanced diagnostics. By delivering unprecedented sensitivity and comprehensive genomic insights, Tempus and Predicta Biosciences are enabling a new era of cancer detection and monitoring. As the adoption of such technologies continues to grow, they are expected to play a critical role in reshaping clinical research, improving therapeutic development, and advancing personalized medicine, offering new hope for patients with hematologic malignancies.

Source: Tempus AI, Predicta Biosciences press release